Illumina and GenoScreen partner to expand access to genomic testing for multidrug-resistant TB

SAN DIEGO, Oct. 18, 2022 -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, today announced a partnership to accelerate progress to end tuberculosis (TB) worldwide. The partnership will expand capabilities for countries most impacted by tuberculosis to more effectively detect and combat multidrug-resistant TB (MDR-TB). This alliance will enable global access to a package combining Illumina sequencing products and the GenoScreen Deeplex^® Myc-TB assay, a targeted next-generation sequencing (NGS) based test for rapid and extensive detection of anti-TB drug resistance, to promptly inform treatment decision. This will help advance the World Health Organization's (WHO) strategy to end the global TB epidemic by 2035.